ERBB2 and breast carcinoma: In the DESTINY-Breast06 trial, among 54 patients who had HER2-low breast cancer with an IHC score of 1+ or 2+ and a negative fluorescence in situ hybridization assay, T-DXd achieved an observed ORR of 37% [40].